Aclaris Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M |
| Cost of revenue | $2.1M | $2.8M | $3.4M | $4.0M | $4.7M |
| Research and development | $52.6M | $33.6M | $98.4M | $77.8M | $43.8M |
| Operating income | -$76.4M | -$141.9M | -$97.4M | -$89.9M | -$89.7M |
| Pretax income | -$64.9M | -$132.1M | -$88.8M | -$86.9M | -$90.9M |
| Income tax expense | — | — | -$367,000 | — | — |
| Net income | -$64.9M | -$132.1M | -$88.5M | -$86.9M | -$90.9M |
| Balance Sheet | |||||
| Cash and equivalents | $20.0M | $24.6M | $39.9M | $45.3M | $27.3M |
| Current assets | $96.3M | $126.0M | $128.9M | $231.6M | $205.0M |
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M |
| Current liabilities | $28.6M | $31.6M | $31.0M | $21.9M | $22.9M |
| Total liabilities | $57.4M | $64.8M | $40.2M | $57.0M | $53.9M |
| Stockholders' equity | $103.1M | $155.6M | $157.2M | $197.6M | $197.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$47.1M | -$20.1M | -$78.3M | -$67.6M | -$52.1M |
| Depreciation and amortization | $454,000 | $807,000 | $863,000 | $797,000 | $923,000 |
| Stock-based compensation | $12.4M | $10.9M | $20.5M | $15.0M | $14.1M |
| Capital expenditure | $111,000 | $121,000 | $1.3M | $605,000 | $308,000 |
| Free cash flow | -$47.2M | -$20.2M | -$79.6M | -$68.2M | -$52.4M |
| Dividends paid | — | — | — | $0 | $0 |
| Impairments | — | — | $6.6M | — | — |
Shares outstanding 139.7M · Free float 65.4%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.